Risperidone-induced neuroleptic malignant syndrome

Area of Science:

• Neuroscience
• Pharmacology
• Clinical Medicine

Background:

• Neuroleptic Malignant Syndrome (NMS) is a rare but life-threatening condition.
• Atypical antipsychotics, such as risperidone, are increasingly used in psychiatric practice.
• Understanding the risk factors and presentation of NMS associated with atypical antipsychotics is crucial.

Observation:

• A case report details an adolescent male who developed NMS.
• The patient experienced NMS after initiating risperidone therapy.
• Symptoms included fever, muscle rigidity, altered mental status, and autonomic dysfunction.

Findings:

• Risperidone, an atypical antipsychotic, was implicated in inducing NMS.
• The patient recovered after discontinuation of risperidone and supportive care.
• Literature review indicates a potential association between risperidone and NMS.

Implications:

• Healthcare providers should exercise caution when prescribing risperidone.
• Awareness of NMS symptoms is vital for early diagnosis and management.
• Further research may be needed to fully elucidate the risk of NMS with risperidone.